Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma

News
Video

Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.

Recent Videos
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Related Content
Rendering of plasma cells

Daratumumab-Based Regimen Sustains Efficacy in Transplant-Ineligible NDMM

Russ Conroy
March 20th 2025
Article

Updated MAIA trial results reinforce the frontline benefit of daratumumab plus lenalidomide/dexamethasone in transplant-ineligible NDMM.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Model of multiple myeloma cells

Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM

Tim Cortese
Published: February 27th 2025 | Updated: March 3rd 2025
Article

Median time to sustained worsening of symptoms was 23.7 months with cilta-cel, compared with 18.9 months with SOC.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Lindsay Fischer
April 13th 2023
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

an illustration of a bone with circles around it indicating a microscope, test tubes and prescriptions

Subcutaneous Isatuximab Non-Inferior to IV in Relapsed/Refractory Myeloma

Caroline Seymour
January 10th 2025
Article

In patients with RRMM, subcutaneous isatuximab plus Pd resulted in a non-inferior objective response rate (ORR) and comparable pre-dose concentrations at steady state compared to IV isatuximab plus Pd.

myeloma

Real-World Use of Ide-cel Provides Favorable Outcomes in CNS Myeloma

Jonah Feldman
December 24th 2024
Article

Patients treated with ide-cel, Abecma for relapsed/refractory multiple myeloma affecting the central nervous system had similar outcomes to matched patients with non-CNS multiple myeloma.